These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20028651)

  • 1. [Lung cancer: an update in 2010].
    Besse B; Vignot S; Soria JC
    Bull Cancer; 2010 Jan; 97(1):161-9. PubMed ID: 20028651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
    Lind JS; Herder GJ; Smit EF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(16):928-32. PubMed ID: 18561788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-small-cell lung cancer].
    Akita H; Kinoshita I
    Gan To Kagaku Ryoho; 2008 May; 35(5):720-4. PubMed ID: 18487906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeted therapies in the treatment of non-small cell lung cancer].
    De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
    Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
    Grenier J; Soria JC
    Bull Cancer; 2007 Jan; 94(1):53-61. PubMed ID: 17237005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 8. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
    Huber RM; Reck M; Thomas M
    Eur Respir J; 2013 Oct; 42(4):1119-33. PubMed ID: 23429914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
    Cortot AB
    Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
    Ostoros G; Döme B; Strausz J; Tímár J
    Magy Onkol; 2010 Jun; 54(2):137-43. PubMed ID: 20576590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW; Choy H
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [EGFR/HER1: a target life].
    Viel E; Curtit E; Mansi L; Vignot S
    Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New advance of the molecular targeting agents in advanced non-small cell lung cancer].
    Zhang L; Cheng ZW; Gao JM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):323-9. PubMed ID: 15266840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?
    Chamberlain MC
    J Clin Oncol; 2013 Sep; 31(25):3164-5. PubMed ID: 23897966
    [No Abstract]   [Full Text] [Related]  

  • 18. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage with erlotinib plus bevacizumab: not in NSCLC.
    Sculier JP; Meert AP; Berghmans T
    Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
    [No Abstract]   [Full Text] [Related]  

  • 20. [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
    Italiano A; Besse B; Planchard D; Soria JC
    Bull Cancer; 2007; 94(7 Suppl):F177-88. PubMed ID: 17964994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.